Oct 2026· Nature Communications· Vol 17· 0 citations· 53 references
Medicine
TL;DR
Although the trial did not meet its prespecified efficacy endpoint, PFS in 6 subjects among this heavily pre-treated cohort highlight the need for biomarkers to select regimens for patients with recurrent ovarian cancer.
Abstract
Response rates to immune checkpoint blockade (ICB) in ovarian cancer are low. In preclinical studies, poly(ADP-ribose) polymerase inhibition (PARPi) synergized with CTLA4 ICB to achieve long-term survival in Brca1-deficient ovarian cancer models. Here we evaluated the safety and efficacy of combined treatment with the PARPi olaparib and the CTLA4 ICB tremelimumab for recurrent epithelial ovarian cancer in a multi-site single-arm phase I/II study enrolling 50 women with germline BRCA1 or BRCA2 mutations (NCT02571725). In phase I, no new toxicities were identified (n = 3). In the combined phase I and II safety cohort (n = 49), 57% of subjects experienced grade 3 or 4 non-hematologic toxicity, with tremelimumab discontinuation in 34.7%. The primary phase II endpoint, overall response rate was 32.7% (95% CI 19.5-45.8%), and disease control rate was 47.7% (95% CI 33.0-62.5%). Secondary outcomes were progression-free survival (PFS, 3.0 months, 95% CI 2.7-5.9), and overall survival (24.3 months, CI 14.9-30.4). In exploratory post-hoc biomarker analyses, low VSTM5 or IFIT1B expression was associated with treatment benefit and improved PFS (p < 0.001). Although the trial did not meet its prespecified efficacy endpoint, PFS > 12 months in 6 subjects among this heavily pre-treated cohort highlight the need for biomarkers to select regimens for patients with recurrent ovarian cancer. Response rate to immune checkpoint blockade (ICB) in ovarian cancer remains low and combinatorial strategies are needed. Here the authors report the results of a phase I/II study of the PARP inhibitor olaparib and the anti-CTLA4 antibody tremelimumab in women with recurrent epithelial ovarian cancer and a germline BRCA1 or BRCA2 mutation.
ABSTRACT Patients with advanced endometrial cancer (EC) have a poor prognosis and limited therapeutic options after failure of prior systemic therapy. In this multi‐cohort Phase II study (ETER200), patients with metastatic or recurrent EC who had received at least one chemotherapy regimen were enrolled. Based on MSI/MM...
Shan-Hui Liang, Xiao-Jun Chen, Ke Wang et al.· MedComm· 0 citations
PURPOSE
VIOLETTE (NCT03330847) assessed olaparib alone or with ceralasertib (ATR inhibitor) or adavosertib (WEE1 inhibitor) as second-/third-line treatment in three molecular strata of patients with previously treated, PARP inhibitor-naïve, advanced triple-negative breast cancer (TNBC).
PATIENTS AND METHODS
Patients...
A. Tutt, Z. Nowecki, R. Szoszkiewicz et al.· Clinical Cancer Research· 0 citations
BACKGROUND
Ceralasertib, an ATR inhibitor, is known to exacerbate replication stress induced by the PARP inhibitor (PARPi) olaparib, with the combination having the potential to overcome PARPi resistance in the clinic. This modular Phase 1 study evaluated the combination in advanced solid tumours, including breast canc...
J. Lopez, Seock-Ah Im, S. Postel-Vinay et al.· British Journal of Cancer· 0 citations
KRAS G12D mutations drive approximately 40% of pancreatic ductal adenocarcinoma (PDAC) cases and foster an immunosuppressive tumor microenvironment. This phase 1/2 trial (NCT06427239) evaluated HRS-4642, a selective KRAS G12D inhibitor, combined with the PD-L1 blockade adebrelimab in 48 pretreated patients with metasta...
S. Shi, Miao-Yan Wei, N. Du et al.· Cancer Cell· 2 citations
Bavdegalutamide had a manageable safety profile and showed promising clinical activity in patients with mCRPC, particularly those with tumors harboring AR T878/H875 mutations.
Xin Gao, B. Garmezy, J. Vuky et al.· Journal of Clinical Oncology· 0 citations
Combining inhibition of poly(ADP-ribose) polymerase and androgen receptor (AR) pathway has demonstrated clinical activity in men with metastatic prostate cancer, although the extent of benefit in tumors lacking homologous recombination repair (HRR) gene alterations remains uncertain. We conducted a randomized phase 2 t...
F. Zacchi, Elena Castro, Kathleen Imbach et al.· Nature Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.